LPTX$2.05
Chart
Performance
Key Stats
AI LPTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldLeap Therapeutics (LPTX) presents a mixed investment profile. While it operates in the promising biopharmaceutical sector with potential for disruptive therapies, its current financial performance, lack of revenue, and significant past losses suggest high risk. Technical indicators are neutral to slightly bearish. It's a speculative play for investors with a high risk tolerance who believe in the long-term potential of its drug pipeline.
Thematic
Leap Therapeutics is positioned within the biopharmaceutical industry, specifically focusing on antibody therapies for cancer treatment. This sector is driven by innovation, unmet medical needs, and demographic trends such as aging populations and increased cancer incidence. The success of its drug pipeline, particularly DKN-01 and FL-501, aligns with thematic trends in personalized medicine and targeted cancer therapies. However, the high failure rate in drug development and lengthy regulatory approval processes present significant thematic risks.
Fundamental
Leap Therapeutics' financial fundamentals are currently weak. The company reports no revenue, significant operating losses, and negative earnings per share. Its cash position is substantial but is being depleted by operating expenses, indicating a need for future financing. The market capitalization is low, reflecting the speculative nature of the company.
Technical
Technical indicators for Leap Therapeutics (LPTX) suggest a largely neutral to slightly bearish short-to-medium term outlook. The stock is trading significantly below its 52-week high, and recent performance shows considerable volatility. Moving averages are mixed across different timeframes, and oscillators offer little conviction for a strong directional move.
| Factor | Score |
|---|---|
| Oncology Market Growth | 80 |
| Biotechnology Innovation | 70 |
| Drug Development Risk | 40 |
| Regulatory Landscape | 60 |
| Partnerships & Collaborations | 70 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 5 |
| Growth | 5 |
| Balance Sheet Health | 50 |
| Cash Flow | 10 |
| Earnings Per Share (EPS) | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 45 |
| Volume Analysis | 40 |
| Price Performance | 20 |
| Support & Resistance | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Short-Term Performance
The stock has shown strong positive returns over the last 1 month (+37.4%) and 5 days (+2.56%), indicating recent positive investor sentiment or momentum.
Positive EPS Surprise in Recent Quarters
Leap Therapeutics (LPTX) has demonstrated positive EPS surprises in multiple recent quarters (e.g., 2024 Q2: 187.18%, 2024 Q1: 16.36%), suggesting the company is exceeding earnings expectations.
Bearish Points (8)
Significant Long-Term Underperformance
The stock has experienced substantial declines over the medium to long term, with a -84.0% performance over 6 months and -83.26% over 1 year, indicating significant challenges or negative market sentiment.
Negative or Uninformative P/E Ratio
The Price-to-Earnings (P/E) ratio is consistently null or negative (e.g., -0.3 TTM, -1.8 for 2024), typical for companies with no earnings, making traditional valuation metrics less applicable and indicating a lack of profitability.
Calendar
August 2025
11
Next Earnings Date
H: $-0.29
A: $-0.29
L: $-0.29
Profile
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 90
Strong oncology pipeline with clinical programs in various cancers, including gastric and colorectal, which are key indications for LPTX's lead asset DKN-01. Potential for direct therapeutic competition.
Weight: 88
Offers Cyramza (ramucirumab), an FDA-approved therapy for advanced gastric cancer. Direct market competitor in LPTX's primary indication.
Weight: 85
Keytruda (pembrolizumab) is a leading immunotherapy approved for gastric and other GI cancers. While a different mechanism, it is a significant competitor in the treatment landscape for LPTX's target indications.
Weight: 85
Opdivo (nivolumab) is another key immunotherapy approved for gastric cancer. BMY also has a broad oncology portfolio, including targeted therapies from recent acquisitions (e.g., Mirati, Turning Point Therapeutics), offering both direct and indirect competition in solid tumors.